Asymptomatic cryptococcal antigenemia is very common in areas with endemic HIV/AIDS, and is associated with increased mortality and incidence of cryptococcal meningitis. Screening is not recommended for HIV/AIDS patients in the United States or Europe. However, screening may be beneficial in countries with limited HAART availability, high levels of antiretroviral drug resistance, and a high burden of disease. In the absence of symptoms, positive cryptococcal antigenemia should be treated with fluconazole 400 mg orally, once daily.
Cryptococcosis screening
Coccidioidomycosis screening
Echinococcosis screening
Mycosis fungoides screening
Langerhans cell histiocytosis screening
Toxoplasmosis screening
Splenic marginal zone lymphoma screening
Lymphomatoid granulomatosis screening